Recommendations of the 2005 Ovarian Cancer State of the Science Meeting
References (0)
Cited by (12)
Clear cell carcinoma of the ovary: A review of the literature
2012, Gynecologic OncologyCitation Excerpt :In 2010, a meta-analysis including data from seven international Phase III platinum-based first-line trials, with over 8000 patients, was published [4]. The analysis included 221 (2.5%) of women with Stage III/IV CCC, who when compared to women with advanced stage serous EOC, were reported to have a less favorable outcome, with increased risk of death (HR = 2.18; 95%CI 1.84–2.57) and disease progression (HR = 1.64; 95%CI 1.41–1.92) [113]. For patients with CCC, median OS was 21.3 months (95% CI 17.8–28.1 months) compared to a median OS of 40.8 months (95% CI 39.7–42.2 months) for women with serous EOC [113].
Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010
2011, Gynecologic OncologyCitation Excerpt :There was no statistical difference between studies with and without centralized pathology review. The authors conclude that the data support recent international collaborative efforts to enrol patients in histology specific studies [96]. Some investigators suggest that CCC may be relatively resistant to standard carboplatin paclitaxel chemotherapy.
Ovarian carcinoma pathology and genetics: recent advances
2009, Human PathologyTumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma
2008, Human PathologyCitation Excerpt :Increasingly, it is appreciated that tumor cell type correlates with epidemiological risk factors, BRCA1 or 2 mutation status, differences in gene expression profile and genetic events during oncogenesis, and response to treatment [4-9]. A recent National Cancer Institute sponsored “State of the Science” conference on ovarian cancer concluded that trials of alternative therapies for clear cell and mucinous carcinoma should be initiated, based on existing evidence that these tumor cell types respond poorly to conventional chemotherapy [10]. Thus, cell type has the potential to convey information about underlying molecular abnormalities and to guide treatment so that the ability to reproducibly assess this variable is important.
Common and specific genes in ovarian clear cell carcinoma and serous carcinoma by gene expression analysis
2018, Translational Cancer ResearchOvarian carcinoma diagnosis: The clinical impact of 15 years of change
2016, British Journal of Cancer